PURPOSE: The optimal therapy of patients with cerebral cavernoma (CCs) and new onset epilepsy, sporadic seizures, or non well established refractory epilepsy is still not clear. The aim of this study was to compare the incidence of seizures in patients with CCs both operated and non operated, in order to obtain more information on the correct management of these patients. MATERIALS AND METHODS: We studied retrospectively 43 patients with non refractory epilepsy secondary to CCs. Twenty-six of them (60.5%) underwent surgery and made up the surgical group, and 17 patients were treated medically and constituted the medical group. Seizure frequency and other clinical variables were compared between both groups. RESULTS: At two years, out of the 26 operated patients, 19 (73%) remained seizure free, 4 (15%) had less than a seizure per month, and one patient (4%) had more than one seizure per month. At five years, 15 patients of the surgical group remained for analysis. Of them, 11 (73.3%) were seizure free, and 4 (26.7%) had less than one seizure a month. In the medical group, 12 out of 17 patients were seizure free (70.6%). There were no significant differences between the two groups (p=0.2 and p=0.3, respectively). Seven patients had postoperative neurological sequelae. CONCLUSION: Surgical treatment of patients with non refractory epilepsy due to CCs did not significantly reduce the likelihood of seizures when compared to medical treatment. It must also be considered that surgery carries serious risks. A prospective and randomized study must be carried out to further clarify our findings.
PURPOSE: The optimal therapy of patients with cerebral cavernoma (CCs) and new onset epilepsy, sporadic seizures, or non well established refractory epilepsy is still not clear. The aim of this study was to compare the incidence of seizures in patients with CCs both operated and non operated, in order to obtain more information on the correct management of these patients. MATERIALS AND METHODS: We studied retrospectively 43 patients with non refractory epilepsy secondary to CCs. Twenty-six of them (60.5%) underwent surgery and made up the surgical group, and 17 patients were treated medically and constituted the medical group. Seizure frequency and other clinical variables were compared between both groups. RESULTS: At two years, out of the 26 operated patients, 19 (73%) remained seizure free, 4 (15%) had less than a seizure per month, and one patient (4%) had more than one seizure per month. At five years, 15 patients of the surgical group remained for analysis. Of them, 11 (73.3%) were seizure free, and 4 (26.7%) had less than one seizure a month. In the medical group, 12 out of 17 patients were seizure free (70.6%). There were no significant differences between the two groups (p=0.2 and p=0.3, respectively). Seven patients had postoperative neurological sequelae. CONCLUSION: Surgical treatment of patients with non refractory epilepsy due to CCs did not significantly reduce the likelihood of seizures when compared to medical treatment. It must also be considered that surgery carries serious risks. A prospective and randomized study must be carried out to further clarify our findings.
Authors: Atif Zafar; Syed A Quadri; Mudassir Farooqui; Asad Ikram; Myranda Robinson; Blaine L Hart; Marc C Mabray; Catherine Vigil; Alan T Tang; Mark L Kahn; Howard Yonas; Michael T Lawton; Helen Kim; Leslie Morrison Journal: Stroke Date: 2019-05 Impact factor: 7.914
Authors: Nikolaos Mouchtouris; Nohra Chalouhi; Ameet Chitale; Robert M Starke; Stavropoula I Tjoumakaris; Robert H Rosenwasser; Pascal M Jabbour Journal: ScientificWorldJournal Date: 2015-01-05
Authors: Fiona Moultrie; Margaret A Horne; Colin B Josephson; Julie M Hall; Carl E Counsell; Jo J Bhattacharya; Vakis Papanastassiou; Robin J Sellar; Charles P Warlow; Gordon D Murray; Rustam Al-Shahi Salman Journal: Neurology Date: 2014-07-03 Impact factor: 9.910
Authors: Bjoern Sommer; Burkhard Sebastian Kasper; Roland Coras; Ingmar Blumcke; Hajo Martinus Hamer; Michael Buchfelder; Karl Roessler Journal: Neurol Res Date: 2013-09-30 Impact factor: 2.448